Cargando…

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases

Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Reis Neto, Edgard Torres, Kakehasi, Adriana Maria, de Medeiros Pinheiro, Marcelo, Ferreira, Gilda Aparecida, Marques, Cláudia Diniz Lopes, da Mota, Licia Maria Henrique, dos Santos Paiva, Eduardo, Pileggi, Gecilmara Cristina Salviato, Sato, Emília Inoue, Reis, Ana Paula Monteiro Gomides, Xavier, Ricardo Machado, Provenza, José Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282202/
https://www.ncbi.nlm.nih.gov/pubmed/32517786
http://dx.doi.org/10.1186/s42358-020-00134-8
_version_ 1783544083680067584
author dos Reis Neto, Edgard Torres
Kakehasi, Adriana Maria
de Medeiros Pinheiro, Marcelo
Ferreira, Gilda Aparecida
Marques, Cláudia Diniz Lopes
da Mota, Licia Maria Henrique
dos Santos Paiva, Eduardo
Pileggi, Gecilmara Cristina Salviato
Sato, Emília Inoue
Reis, Ana Paula Monteiro Gomides
Xavier, Ricardo Machado
Provenza, José Roberto
author_facet dos Reis Neto, Edgard Torres
Kakehasi, Adriana Maria
de Medeiros Pinheiro, Marcelo
Ferreira, Gilda Aparecida
Marques, Cláudia Diniz Lopes
da Mota, Licia Maria Henrique
dos Santos Paiva, Eduardo
Pileggi, Gecilmara Cristina Salviato
Sato, Emília Inoue
Reis, Ana Paula Monteiro Gomides
Xavier, Ricardo Machado
Provenza, José Roberto
author_sort dos Reis Neto, Edgard Torres
collection PubMed
description Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.
format Online
Article
Text
id pubmed-7282202
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72822022020-06-09 Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases dos Reis Neto, Edgard Torres Kakehasi, Adriana Maria de Medeiros Pinheiro, Marcelo Ferreira, Gilda Aparecida Marques, Cláudia Diniz Lopes da Mota, Licia Maria Henrique dos Santos Paiva, Eduardo Pileggi, Gecilmara Cristina Salviato Sato, Emília Inoue Reis, Ana Paula Monteiro Gomides Xavier, Ricardo Machado Provenza, José Roberto Adv Rheumatol Position Article and Guidelines Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs. BioMed Central 2020-06-09 2020 /pmc/articles/PMC7282202/ /pubmed/32517786 http://dx.doi.org/10.1186/s42358-020-00134-8 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Position Article and Guidelines
dos Reis Neto, Edgard Torres
Kakehasi, Adriana Maria
de Medeiros Pinheiro, Marcelo
Ferreira, Gilda Aparecida
Marques, Cláudia Diniz Lopes
da Mota, Licia Maria Henrique
dos Santos Paiva, Eduardo
Pileggi, Gecilmara Cristina Salviato
Sato, Emília Inoue
Reis, Ana Paula Monteiro Gomides
Xavier, Ricardo Machado
Provenza, José Roberto
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
title Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
title_full Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
title_fullStr Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
title_full_unstemmed Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
title_short Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
title_sort revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
topic Position Article and Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282202/
https://www.ncbi.nlm.nih.gov/pubmed/32517786
http://dx.doi.org/10.1186/s42358-020-00134-8
work_keys_str_mv AT dosreisnetoedgardtorres revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT kakehasiadrianamaria revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT demedeirospinheiromarcelo revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT ferreiragildaaparecida revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT marquesclaudiadinizlopes revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT damotaliciamariahenrique revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT dossantospaivaeduardo revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT pileggigecilmaracristinasalviato revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT satoemiliainoue revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT reisanapaulamonteirogomides revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT xavierricardomachado revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases
AT provenzajoseroberto revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases